Medically reviewed by Anisha Shah, MD Ischemia occurs when the heart does not receive adequate blood supply to function ...

Following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial evaluating aficamten, a next-in-class cardiac myosin inhibitor, in obstructive hypertrophic cardiomyopathy (HCM), ...

Analyst Roanna Ruiz of Leerink Partners maintained a Buy rating on Cytokinetics (CYTK – Research Report), reducing the price target to ...

The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex ...

KMC Hospital in Mangaluru successfully treats Rev Fr Wolfgang Leonhard, a German priest, diagnosed with hypertrophic obstructive cardiomyopathy and complete heart block. The cardiology team implanted ...

A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.

The patient was diagnosed with Hypertrophic Obstructive Cardiomyopathy (HOCM), a genetic heart condition that led to severe ...

BACKGROUND: Patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction commonly experience ...

In a remarkable display of expertise and advanced cardiac care, KMC Hospital, Dr B R Ambedkar Circle successfully treated Fr Wolfgang Leonhard, a 65-year-old German national, who was rushed to the ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2024 and recent business highlights.

Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of ...

Background: Approximately half of hypertrophic cardiomyopathy (HCM) patients lack a precise genetic diagnosis. The likelihood of identifying clinically relevant variants increased over time. Methods: ...